Vitestro is turning autonomous blood draws into a supervised clinical workflow layer

Vitestro raised $70 million in Series B financing on March 10, 2026, after receiving European CE marking for its Aletta autonomous blood-drawing device in 2024. Strategic healthcare investors in the round included Labcorp Venture Fund, Mayo Clinic, and Sutter Health.

Aletta performs the diagnostic blood draw workflow from tourniquet placement to bandage application. The device uses multimodal vein imaging and Doppler confirmation before needle insertion, then handles tube changing and inversion during collection. Vitestro says one trained supervisor can oversee up to three Aletta devices, framing the product as supervised clinical automation rather than fully unattended phlebotomy.

Vitestro received CE marking under the European Medical Device Regulation, then planned a limited market release across selected European hospitals and clinical laboratories before broader production scale-up. Source

Vitestro reports EU A.D.O.P.T. trial results with a 94.5% first-stick success rate, and patient-facing material says 90% of patients rated pain as similar to or lower than manual blood collection. CORDIS reporting for the Horizon Europe VD-1 project records the first 1,400 enrolled patients across four European hospital laboratory sites and notes that Vitestro developed the technology in-house with seven patents. Source

Aletta combines vein imaging and blood collection in a supervised device with CE marking and clinical trial data. It covers more of the collection workflow than venipuncture-assist devices.

Have a robotics update Korthos should review? Send news, deployments, product releases, funding rounds, research, or media to [email protected] or reach out on X at @agkorthos.